Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05610475

Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass

Conditions: Lung Injury, Acute

Sex: All
Ages: 18 Years – N/A
Phase: NA
Enrollment: 100
Sponsor: Yangzhou University

Location: China

Summary

More than 2 million patients worldwide receive heart surgery every year, majority of these surgical patients will undergo cardiopulmonary bypass. However, the incidence of postoperative acute lung injury due to cardiopulmonary bypass is still as high as 20% to 35%. According to clinical experience, the earlier lung damage is detected, the more successful the treatment will be. On the basis of traditional detection, the investigators found a new indicator, serum calpains, which are easy to obtain and have certain specificity. Importantly, they can predict postoperative acute lung injury within 1 hour after cardiac surgery. It is meaningful that this indicator can provide clinicians with early decision-making advice and immediate treatment for patients who may be at risk.

Eligibility Criteria

Inclusion Criteria:Age ≥ 18 years;Underwent cardiac surgery using CPB technology.Exclusion criteria :Patient's lack of consent to participate;Presence of abnormal liver, kidney or other organ function;Pulmonary inflammation, chronic obstructive pulmonary disease or tumors;Underwent cardiac surgery without CPB technology;Postoperative need for extracorporeal membrane oxygenation support.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05610475). StuddyBuddy aggregates publicly available trial information.